Matthew Kapusta Sells 164,429 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 164,429 shares of uniQure stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total value of $7,287,493.28. Following the transaction, the chief executive officer owned 558,810 shares in the company, valued at approximately $24,766,459.20. This represents a 22.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Up 10.5%

Shares of uniQure stock opened at $49.04 on Wednesday. The company has a market capitalization of $3.09 billion, a P/E ratio of -14.09 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The business has a 50-day moving average of $25.97 and a two-hundred day moving average of $22.47. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. As a group, equities analysts predict that uniQure N.V. will post -3.64 EPS for the current year.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported promising early results from its AMT-260 epilepsy program, with initial patients showing large seizure reductions and no treatment-related serious adverse events, supporting confidence in the company’s gene-therapy pipeline. Article Title
• Positive Sentiment: Several news outlets highlighted early AMT-260 data showing seizure reductions of 79% to 100% in three patients, which is helping fuel investor enthusiasm for the stock. Article Title
• Positive Sentiment: Analysts remain bullish on QURE, with recent upgrades and higher price targets reinforcing the view that the latest pipeline progress could create additional upside. Article Title
• Neutral Sentiment: The company also announced preliminary Phase I/IIa data for AMT-260, which is an important but expected clinical milestone for a development-stage biotech. Article Title
• Negative Sentiment: uniQure launched a proposed $150 million public offering, plus a potential $22.5 million greenshoe, which could dilute existing shareholders even as it strengthens the balance sheet. Article Title
• Negative Sentiment: Recent insider selling by the CEO and two directors may weigh on sentiment, even though the trades were made under pre-arranged 10b5-1 plans. Article Title

Analysts Set New Price Targets

QURE has been the subject of several research reports. Royal Bank Of Canada increased their price objective on shares of uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Stifel Nicolaus set a $28.00 target price on shares of uniQure in a research note on Tuesday, May 5th. TD Cowen reiterated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Finally, Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a research note on Wednesday, June 17th. Twelve research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and an average target price of $58.92.

Hedge Funds Weigh In On uniQure

Hedge funds have recently made changes to their positions in the business. State Street Corp grew its position in uniQure by 123.8% in the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. lifted its position in uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after buying an additional 1,785,275 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after buying an additional 1,705,556 shares during the last quarter. Orbimed Advisors LLC boosted its stake in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after buying an additional 1,398,749 shares during the last quarter. Finally, MPM Bioimpact LLC acquired a new stake in shares of uniQure in the fourth quarter valued at about $33,062,000. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.